ZA200106488B - N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. - Google Patents

N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance.

Info

Publication number
ZA200106488B
ZA200106488B ZA200106488A ZA200106488A ZA200106488B ZA 200106488 B ZA200106488 B ZA 200106488B ZA 200106488 A ZA200106488 A ZA 200106488A ZA 200106488 A ZA200106488 A ZA 200106488A ZA 200106488 B ZA200106488 B ZA 200106488B
Authority
ZA
South Africa
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
ZA200106488A
Other languages
English (en)
Inventor
Maria Kuerthy
Katalin Biro
Karoly Nagy
Laszlo Uroegdi
Zita Csakai
Jenoe Szilbereky
Tamas Mogyorosi
Magdolna Toeroek
Andras Komaromi
Ede Marvanyos
Mihaly Barabas
Mihalyne Kardos
Zoltan Nagy
Laszlo Koranyi
Melinda Nagy
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of ZA200106488B publication Critical patent/ZA200106488B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200106488A 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance. ZA200106488B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component

Publications (1)

Publication Number Publication Date
ZA200106488B true ZA200106488B (en) 2002-08-07

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200106488A ZA200106488B (en) 1999-02-26 2001-08-07 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance.

Country Status (27)

Country Link
US (1) US6649628B1 (xx)
EP (1) EP1163224B1 (xx)
JP (1) JP4689838B2 (xx)
KR (1) KR100676124B1 (xx)
AT (1) ATE237590T1 (xx)
AU (1) AU779096B2 (xx)
BG (1) BG65178B1 (xx)
BR (1) BR0008969A (xx)
CA (1) CA2360451C (xx)
CZ (1) CZ297386B6 (xx)
DE (1) DE60002187T2 (xx)
DK (1) DK1163224T3 (xx)
EE (1) EE04961B1 (xx)
ES (1) ES2193055T3 (xx)
HR (1) HRP20010584B1 (xx)
HU (1) HUP9900475D0 (xx)
IL (2) IL144866A0 (xx)
NO (1) NO319793B1 (xx)
PL (1) PL197692B1 (xx)
PT (1) PT1163224E (xx)
RS (1) RS50083B (xx)
RU (1) RU2250901C2 (xx)
SI (1) SI1163224T1 (xx)
SK (1) SK287063B6 (xx)
UA (1) UA72495C2 (xx)
WO (1) WO2000050403A1 (xx)
ZA (1) ZA200106488B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
WO2003057664A1 (en) 2002-01-11 2003-07-17 Biorex Kutató És Fejlesztö Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
HUE025852T2 (en) 2008-06-26 2016-04-28 Orphazyme Aps Use of HSP70 to regulate enzyme activity
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
US9837727B2 (en) 2012-09-14 2017-12-05 Saint-Gobain Glass France Pane having an electrical connection element
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
PL3193840T3 (pl) * 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
RS61291B1 (sr) * 2016-04-29 2021-02-26 Orphazyme As Arimoklomol za lečenje poremećaja povezanih sa glukocerebrozidazom
CN110753544A (zh) 2017-05-24 2020-02-04 奥菲泽米有限公司 热激蛋白诱导物和额颞病况
CN112166326A (zh) 2018-05-28 2021-01-01 奥菲泽米有限公司 Pbmc样本中的hsp70蛋白水平作为疾病的生物标记物
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
CA3183559A1 (en) 2020-06-24 2021-12-30 Thomas Kirkegaard Jensen Arimoclomol for treating gaucher disease
MX2023005954A (es) * 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.
JP2024502304A (ja) 2020-12-24 2024-01-18 ゼブラ デンマーク エー/エス Er型ミスセンス変異を有する患者におけるニーマンピック病c型の治療用アリモクロモル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
AU779096B2 (en) 2005-01-06
SK11582001A3 (sk) 2001-12-03
KR100676124B1 (ko) 2007-01-31
PL197692B1 (pl) 2008-04-30
BG65178B1 (bg) 2007-05-31
EE200100447A (et) 2002-12-16
NO20014103D0 (no) 2001-08-23
NO20014103L (no) 2001-10-22
EP1163224B1 (en) 2003-04-16
PT1163224E (pt) 2003-07-31
EE04961B1 (et) 2008-02-15
BG105837A (en) 2002-03-29
RU2250901C2 (ru) 2005-04-27
ATE237590T1 (de) 2003-05-15
CA2360451C (en) 2011-01-04
HRP20010584B1 (en) 2010-08-31
WO2000050403A1 (en) 2000-08-31
JP2002537384A (ja) 2002-11-05
JP4689838B2 (ja) 2011-05-25
US6649628B1 (en) 2003-11-18
DK1163224T3 (da) 2003-08-04
HUP9900475D0 (en) 1999-04-28
RS50083B (sr) 2009-01-22
BR0008969A (pt) 2001-11-27
NO319793B1 (no) 2005-09-12
DE60002187T2 (de) 2003-12-11
HRP20010584A2 (en) 2002-08-31
KR20010102410A (ko) 2001-11-15
DE60002187D1 (de) 2003-05-22
CZ297386B6 (cs) 2006-11-15
IL144866A (en) 2007-07-04
CZ20013053A3 (cs) 2002-01-16
SK287063B6 (sk) 2009-10-07
UA72495C2 (uk) 2005-03-15
AU3182400A (en) 2000-09-14
YU60301A (sh) 2004-05-12
ES2193055T3 (es) 2003-11-01
EP1163224A1 (en) 2001-12-19
CA2360451A1 (en) 2000-08-31
SI1163224T1 (en) 2003-08-31
IL144866A0 (en) 2002-06-30
PL350915A1 (en) 2003-02-10

Similar Documents

Publication Publication Date Title
IL144866A0 (en) N- [2-hydroxy-3- (1-piperidinyl) propoxy] pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
CA2332521A1 (en) Pharmaceutical composition for treating or preventing sleep disorders
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
CA2361834A1 (en) Offset ablation profiles for treatment of irregular astigmatism
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
IL138723A0 (en) Antitumor agent
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
HK1045524B (zh) 具有抗痴呆作用的5-羥皂草苷配基衍生物
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
TR200101980T2 (tr) Arilalkanoil türevleri, bunların preparasyon işlemleri
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
ZA200102727B (en) Method of treating sickle cell disease or thalassemia.
HK1050203A1 (en) Novel fusidic acid derivatives.
MXPA05014081A (es) Derivados de benzofurano y su uso en el tratamiento de infecciones microbianas.
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic
SE9902674D0 (sv) New composition